Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...

Luke Miels, Chief Commercial Officer, GSK, said: "IDRX-42 complements our growing portfolio in gastrointestinal ... despite existing approved products." Tony Wood, Chief Scientific Officer ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.